Juvenile Arthritis News

Black children with lupus are significantly more likely than white children to have an adverse renal outcome at any hospital encounter, despite an overall decrease in said outcomes since 2006, according to data presented at ACR Convergence 2021.

Eye exam reminders at every visit are associated with higher uveitis knowledge among patients with juvenile idiopathic arthritis and their parents, according to data published in Pediatric Rheumatology.

The FDA has approved a supplemental new drug application for ANI Pharmaceutical’s Cortrophin Gel to treat rheumatoid arthritis, multiple sclerosis and certain other autoimmune diseases, according to a company press release.

The total annual costs for the family of a patient with juvenile idiopathic arthritis are substantial, ranging from $1,122 to $44,832, with the highest dollar amounts spent on medication and medical appointments, according to data.

The fight against COVID-19 has shifted drastically since the beginning of 2021. The front lines are no longer nursing homes or retirement communities, but school cafeterias and daycare centers.

Exposure to antibiotics in early life is associated with the later onset of juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

Enthesitis-related arthritis and a family history of autoimmune disease are key risk factors for inflammatory bowel disease in juvenile idiopathic arthritis, according to data published in Rheumatology.

Healio announced the launch of Rheum and Boards, a quiz-based, online learning resource for rheumatologists, according to a Healio press release.

Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely from national essential medicines lists in close to two-thirds of all countries in the world, according to data published in Pediatric Rheumatology.

In a disturbing repeat of last year’s run on hydroxychloroquine, U.S. health care systems are scrambling to maintain tocilizumab access for rheumatology patients following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases.